Glioblastomas shed large quantities of small, membranebound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a highly sensitive and rapid analytical technique for profiling circulating microvesicles directly from blood samples of patients with glioblastoma. Microvesicles, introduced onto a dedicated microfluidic chip, are labeled with target-specific magnetic nanoparticles and detected by a miniaturized nuclear magnetic resonance system. Compared with current methods, this integrated system has a much higher detection sensitivity and can differentiate glioblastoma multiforme (GBM) microvesicles from nontumor host cellderived microvesicles. We also show that circulating GBM microvesicles can be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. This platform could provide both an early indicator of drug efficacy and a potential molecular stratifier for human clinical trials.
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Glioblastomas shed large quantities of small, membranebound microvesicles into the circulation. Although these hold promise as potential biomarkers of therapeutic response, their identification and quantification remain challenging. Here, we describe a highly sensitive and rapid analytical technique for profiling circulating microvesicles directly from blood samples of patients with glioblastoma. Microvesicles, introduced onto a dedicated microfluidic chip, are labeled with target-specific magnetic nanoparticles and detected by a miniaturized nuclear magnetic resonance system. Compared with current methods, this integrated system has a much higher detection sensitivity and can differentiate glioblastoma multiforme (GBM) microvesicles from nontumor host cellderived microvesicles. We also show that circulating GBM microvesicles can be used to analyze primary tumor mutations and as a predictive metric of treatment-induced changes. This platform could provide both an early indicator of drug efficacy and a potential molecular stratifier for human clinical trials.
Many cancers shed materials into the peripheral circulation such as circulating tumor cells (CTCs) 1 and soluble proteins 2, 3 , which are being exploited as surrogate markers of tumor staging and response to therapy. Systemic and intracranial tumors also release microvesicles [4] [5] [6] into the peripheral circulation. In particular, tumors of the central nervous system, lying behind a partially intact blood-brain barrier, often do not release CTCs and are not commonly associated with detectable soluble protein biomarkers. Large quantities of microvesicles, however, have been found within blood of patients with GBM 3, 5 , and these thus offer a potential new way for treatment monitoring of this devastating disease.
Microvesicles in circulation are made up of membrane-bound vesicles (50 nm-1 µm in diameter), which differ in their cellular origin, abundance and biogenesis 4 . The population includes exosomes (50-100 nm and positive for CD63, heat shock protein 90 (HSP90) and flotillins) released from multivesicular endosomes, larger shed microvesicles, membrane particles, apoptotic vesicles and exosome-like vesicles originating from multivesicular bodies of other cell organelles 4, 7, 8 . Different subtypes of microvesicles can have overlapping size and often co-purify if separated by size only 4, 9 . Microvesicles contain cell surface proteins 10 , including epidermal growth factor receptor (EGFR) and EGFRvIII 6, 11 , as well as RNA 5 and DNA 12 . Current molecular analyses of microvesicles generally require large numbers of microvesicles to be concentrated and processed using time-consuming western blotting or ELISA, making them impractical in a typical clinical setting.
Herein, we describe a highly sensitive and rapid analytical technique for profiling proteins in microvesicles from GBM cell cultures and from blood samples from patients with GBM. We use both size (vesicles 50-150 nm) and immunoaffinity (CD63 + ) to define a population of circulating microvesicles, which consist primarily of exosomes. We label the microvesicles with target-specific magnetic nanoparticles (MNPs) and detect them with a miniaturized micronuclear magnetic resonance (µNMR) system 13, 14 . A prototype µNMR system was previously used to detect whole tumor cells (>10 µm target size range) 15 . Adapting µNMR to microvesicle detection, however, presented considerable engineering challenges because these targets are smaller than tumor cells by one to two orders of magnitude. We thus developed a new microfluidic system and analytical technology specifically for microvesicle detection and profiling that can differentiate glioma-derived microvesicles from host cell-derived microvesicles in patients with GBM. We used this technology to evaluate the comparative protein profiles of glioma-derived microvesicles against those from parental GBM cells. We likewise report on the ability of this system to detect specific circulating microvesicles from blood of patients with GBM and control subjects without GBM and discuss whether circulating microvesicles can be used in longitudinal studies to monitor and predict response to GBM therapies.
RESULTS
Magnetic nanosensor technology for microvesicle detection GBM cell lines in culture produced abundant microvesicles (Fig. 1a) . Microvesicle counting based on nanoparticle tracking analysis (NTA;
Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy t e c h n i c a l r e p o r t s 1 8 3 6 VOLUME 18 | NUMBER 12 | DECEMBER 2012 nature medicine Supplementary Fig. 1a ) reported a typical concentration of 10 8 -10 9 microvesicles per milliliter in culture medium. In situ scanning electron microscopy analysis of microvesicles on cell surfaces revealed that many of the microvesicles were saucer-shaped 16 , a pattern typical of exosomes (Fig. 1b) . For detection by microfluidic µNMR, we purified and labeled microvesicles with MNPs (core diameter 7 nm) by targeting microvesicle protein markers (Fig. 1c) . Such magnetic labeling renders microvesicle superparamagnetic, which results in faster decay of the 1 H NMR signal. The decay rate (R 2 ) is proportional to the MNP concentration, thus enabling the quantification of target microvesicle protein concentration. We used a two-step bio-orthogonal approach (BOND-2; Fig. 1d ) for MNP labeling. Microvesicle protein markers were first targeted with antibodies modified with trans-cyclooctene (TCO) and then coupled with MNPs derivatized with 1,2,4,5-tetrazine (TZ). The fast, covalent cycloaddition between TZ and TCO maximizes MNP binding and increases the magnetic signals (R 2 ) by >300% compared to that achieved by direct MNP-antibody conjugation 17 . Because both TZ and TCO are small (~200 Da each), this chemical conjugation does not appreciably increase the size of the antibody or the MNP. It is thus possible to use size-selective filtration to remove excess antibodies or MNPs while retaining targeted microvesicles. Figure 1e shows a prototype device developed for clinical point-of-care microvesicle analysis. It contains three essential components: (i) a chaotic mixer for reacting microvesicles with antibodies and MNPs, (ii) a membrane filter for washing and concentrating targeted microvesicles and (iii) a microcoil for NMR detection (sample volume: 1 µl). Microvesicles purified by the microfluidic device typically have a size distribution ranging from 50 to 150 nm (with >75% smaller than 120 nm in diameter), owing to the cut-off sizes of membrane filtration (Supplementary Fig. 1b) . To streamline the assay procedure ( Supplementary Fig. 2 ), the fluidic flow is controlled by automated pneumatic valves (Supplementary Fig. 3 ). In a series of microvesicle dilution assays, µNMR was considerably more sensitive than western blotting (WB; Supplementary Fig. 4b ), flow cytometry (FC), ELISA and NTA. All measurements in a-c were performed in triplicate, and the data are mean ± s.e.m. Optimized assay for microvesicle protein typing We hypothesized that in multicellular environments CD63 expression might be used as an internal measure of total microvesicle counts from different cell sources (Supplementary Fig. 4a ) 4, 7 . Figure 2 summarizes the results of the validation study. When we analyzed microvesicles for CD63 expression, the corresponding R 2 changes (∆R 2 CD63 ) were linearly proportional to microvesicle counts, which we independently confirmed by NTA (Fig. 2a) . Notably, these R 2 changes were statistically identical even among microvesicles from different cell lines (P > 0.16). The µNMR measurements were highly reproducible and accurate with <1% instrumental errors. We then determined the expression levels of other protein biomarkers by normalizing the marker-associated ∆R 2 mAb by ∆R 2 CD63 (ξ mAb = ∆R 2 mAb /∆R 2 CD63 ), where mAb is a monoclonal antibody specific for a target biomarker. Such normalization automatically accounts for differences in microvesicle counts, obviating the need to quantify microvesicles by other measures such as NTA. The µNMR also showed excellent agreement (R 2 > 99%) with fluorescence ELISA (Fig. 2b) , and its detection sensitivity (Fig. 2c) far surpassed that of other analytical methods, being 10 4 -, 10 3 -and 10 2 -fold more sensitive than western blotting, ELISA and NTA respectively ( Fig. 2d and Supplementary Fig. 4b ). Given that µNMR detection sensitivity depends on biomarker protein integrity, we also tested the detection level as a function of time ( Supplementary Fig. 5a ) and found that signal degradation can be largely prevented by fixation (Supplementary Fig. 5b ).
Microvesicle molecular signature for GBM detection We next determined whether GBM-derived microvesicles show similar protein profiles to those of intact parental cells and whether we could use molecular markers to differentiate between GBM and host cell (non-GBM) microvesicles. On the basis of prior reports 3,4,18 , we measured expression of the following seven extravesicular and two intravesicular protein markers: EGFR 11 , platelet-derived growth factor receptor (PDGFR-α) 19 , podoplanin (PDPN) 20 , ephrin type-A receptor 2 (EphA2) 21 for their elevated expression in glioma; EGFRvIII 6 and cytosolic isocitrate dehydrogenase 1 mutation (IDH1 R132H) 22, 23 (Fig. 3a) . GBM-derived microvesicles have a distinct molecular signature; elevated expression of EGFR, EGFRvIII, PDPN and IDH1 R132H together allowed for effective discrimination of GBM and host cell microvesicles.
We next profiled microvesicles from blood samples of patients with GBM (n = 24) and healthy volunteers (n = 8; Supplementary Table 1 ). Samples for this study had been selected in a blinded fashion but were enriched in samples positive for EGFR amplification or EGFRvIII mutation. For each patient, there was considerable heterogeneity in the expression levels of individual markers (Supplementary Fig. 6a ). The waterfall plot for each marker revealed a broad spectrum of expression level (Fig. 3b) . Consistent with a previous report 22 , IDH1 R132H, albeit highly specific to GBM, showed low prevalence in patients with primary GBM. The accuracy of each marker in GBM detection, obtained from the receiver operating characteristic (ROC) curves, was <76% ( Fig. 3c and Supplementary Fig. 6b ). Using a four-GBM marker combination (EGFR, EGFRvIII, PDPN and IDH1 R132H), GBMderived microvesicles could be distinguished from host cell-derived microvesicles. HBMVEC, human brain microvascular endothelial cell; NHA, normal human astrocyte; buffy coat and plasma were isolated from whole blood donated by healthy volunteers. (b) Analysis of clinical patient samples. Waterfall plots show the expression levels of different biomarkers sorted from high (left) to low (right). In patient-derived samples, there was higher expression of EGFR and PDPN in addition to unique expression of EGFRvIII and IDH1 R132H. (c) ROC curves (left) were used to determine the detection sensitivity, specificity and accuracy of each marker. Although the overall accuracy for a single marker alone (right) was <76%, when all markers were combined (Quad) the detection accuracy was >90%. AUC, area under curve.
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However, after combining the results of all four markers, we increased the accuracy to >90% (Supplementary Table 2 ).
Efficacy of drug treatment revealed by microvesicles
We investigated the potential use of microvesicles for monitoring treatment responses. Two drug regimens were selected: (i) an alkylating agent, temozolomide (TMZ), which is a first-line adjuvant drug currently used with concomitant radiation therapy for the treatment of newly diagnosed GBM; and (ii) an HSP90 inhibitor, geldanamycin (17AAG), whose binding to HSP90 can enhance the degradation of signaling molecules (for example, EGFR) [25] [26] [27] . Treatment effects on T103 mouse GBM cells and microvesicles are compared in Supplementary Figure 7 for TMZ and Figure 4 for geldanamycin. TMZ treatment did not elicit significant changes in the cellular expression of CD63, EGFR or EGFRvIII, as determined by flow cytometry and western blotting (Supplementary Fig. 7a) . Likewise, corresponding µNMR assays on microvesicles showed that expression levels for EGFR and EGFRvIII are comparable to those observed by flow cytometry and western blotting (Supplementary Fig. 7b ). TMZ treatment, however, resulted in a dose-dependent decrease in both cell and microvesicle counts (Supplementary Fig. 7c) . Total microvesicle expression of CD63, EGFR and EGFRvIII, as measured by the µNMR, thus showed a similar dose-dependent decline, with increasing concentration of TMZ applied (Supplementary Fig. 7d) .
In contrast to TMZ, geldanamycin resulted in a significant decrease in EGFR and EGFRvIII expression, but not in CD63 expression, for both cells and microvesicles (Fig. 4a,b) . Consequently, as microvesicle numbers decreased in proportion to drug concentration (a change attributed to cell loss; Fig. 4c) , the total microvesicle expression of EGFR and EGFRvIII each showed a much more pronounced decline than microvesicle CD63 expression (Fig. 4d) . To account for such additive effects, we defined a drug response index (RI) as Owing to geldanamycin's ability to reduce both microvesicle number as well as receptor expression, tits RI was higher for both T103 and GLI36vIII cell lines compared to TMZ. All changes with respect to untreated samples were statistically significant (P < 0.001). All analytical measurements were performed in triplicate, and the data are shown as mean ± s.e.m. RI = [(1−∆n) + Σ(1−∆ξ k )] / N, where 1−∆n and 1−∆ξ k are the relative changes in glioma microvesicle numbers and microvesicle biomarker expression levels respectively, and N is the total number of markers monitored (k, biomarkers used). Conversely, the complementary of RI was defined as a tumor progression index (TPI = 1−RI). A plot of RI captured the drug efficacies of TMZ and geldanamycin (Fig. 4e) . These findings were corroborated in repeated studies with the human GBM GLI36vIII line, which showed nearly identical trends ( Fig. 4f and Supplementary Fig. 8 ), indicating that normalized detection of microvesicle biomarkers is highly sensitive to reveal the differences between treatment mechanisms.
Circulating microvesicles predict drug efficacy in vivo
We applied the platform to monitor treatment effects in vivo. We first used a mouse model with xenografted human GBM 28 . Circulating microvesicles in cohorts of T103 tumor-bearing mice were profiled during tumor growth as well as after TMZ treatment (80 mg per kg body weight daily). In untreated mice, the TPI increased over time and paralleled tumor volume measured by MRI (Fig. 5a) . In TMZtreated mice, TPI changes occurred several days before reductions in tumor volume as measured by imaging (Fig. 5b) . To visualize the temporal onset of therapeutic effects, we plotted an efficacy index (η MV ), defined as the temporal change in 1/TPI. The efficacy index η MV was close to zero for expanding tumors (Fig. 5c) . Upon TMZ administration, however, η MV rose rapidly, indicating the effectiveness of the treatment. We next extended the study to patients with GBM whose blood samples were collected before and after standard-of-care TMZ and radiation treatment (Supplementary Table 3 ). In this longitudinal study, the TPI was evaluated as samples became available. Responder and nonresponder status was later defined by a neuro-oncologist without knowledge of the µNMR results and based on subsequent clinical and magnetic resonance imaging (MRI) data. TPI allowed the identification and prediction of treatment outcomes, especially for nonresponding cases (Fig. 5d) . The corresponding efficacy index (η MV ) also showed significant difference (P < 0.005) between responders and nonresponders (Fig. 5e) . DISCUSSION GBM is the most common primary malignancy of the central nervous system 29, 30 . Amplification of EGFR is the most frequent genetic abnormality associated with GBM, and EGFR overexpression has been shown in up to 85% of cases 29 . GBM also often expresses EGFRvIII, a genomic deletion variant of EGFR that is constitutively active and highly oncogenic 31, 32 . It is likely that the recent identification of circulating microvesicles containing EGFRvIII-specific RNA 5 and GBM-associated proteins 10 will not only be immediately relevant to this subset of patients with GBM but could also be expanded to other GBM-mutation evaluation. Likewise, circulating microvesicles may provide new avenues for cancer diagnostics and expand our understanding of cellular communication.
Evaluating circulating microvesicles could lead to a paradigm shift in clinical care. Phase 1 and phase 2 trials of targeted agents presently require molecular stratification of GBM tumors. In addition, there remains an urgent need to provide sequential indices of tumor molecular response to these agents. Although imaging remains useful as a clinical tool, the standard RECIST (response evaluation criteria in solid tumors) and volumetric criteria of response are insensitive therapeutic markers in patients receiving vascular-targeted agents such as bevacizumab. New and more sensitive imaging approaches [33] [34] [35] [36] are currently in development; however, they are not universally available, are often expensive 37 and are impractical for rapid sequential evaluations. As a result, there has been intense interest in finding serologic biomarkers for GBM.
Our findings show that GBM-derived circulating microvesicles can be rapidly detected in clinical blood samples with high sensitivity using a nanotechnology-inspired biosensor. The system combines on-chip microfiltration and µNMR principles to enable quantitative detection of microvesicle numbers and protein expression. Measurements are performed on small sample volumes without the need for extensive purification or time-consuming detection techniques. By employing a bioorthogonal targeting approach to specifically target and densely pack MNPs onto microvesicles, the current platform has achieved a detection sensitivity that surpasses standard ELISA and flow cytometry analyses by several orders of magnitude (Fig. 2) . We believe that this could be further enhanced with the use of newer magnetic nanomaterials (with higher magnetization) 38 , improved assay types, additional amplification steps and new bioorthogonal approaches. Likewise, further device optimizations are expected. By incorporating a differential, multistep filtering system, microvesicles can be isolated from whole cells; multiple microcoils can be embedded for extensive parallel profiling of a larger number of microvesicle proteins. Such a system could realize a comprehensive yet portable lab-on-a-chip for microvesicle analysis.
We further envision other clinical applications in which protein typing of circulating microvesicles would be useful. The above-described methodology could be extended to examine other primary tumors, particularly because many cancers secrete much greater quantities of circulating microvesicles than they do of CTCs. It could also be adapted to monitor circulating microvesicles in a variety of inflammatory and infectious diseases, using blood samples, cerebrospinal fluid, urine, saliva or other biofluids. With its capacity for molecular diagnostics at the bedside, the developed platform could potentially redefine the current standard of care for patients.
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
